{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:18:53Z","timestamp":1779297533698,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,5]]},"DOI":"10.7759\/cureus.18513","type":"journal-article","created":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T20:46:07Z","timestamp":1633466767000},"source":"Crossref","is-referenced-by-count":6,"title":["Prolonged-Release Buprenorphine Therapy in Opioid Use Disorder Can Address Stigma and Improve Patient Quality of Life"],"prefix":"10.7759","author":[{"given":"Lorenzo","family":"Somaini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Vecchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"Corte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aisling","family":"Mahony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Pitts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Cutuli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosetta","family":"Orso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Littlewood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfda.2013.09.038","article-title":"Family and social aspects of substance use disorders and treatment","volume":"21","author":"Daley DC","year":"2013","unstructured":"Daley DC. Family and social aspects of substance use disorders and treatment. J Food Drug Anal. 2013, 21:S73-6. 10.1016\/j.jfda.2013.09.038","journal-title":"J Food Drug Anal"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/10509674.2015.1043479","article-title":"Income Generation in recovering Heroin users: a comparative analysis of legal and illegal earning","volume":"54","author":"Callahan S","year":"2015","unstructured":"Callahan S, LoSasso A, Olson B, Beasley C, Nisle S, Campagna K, Jason LA. Income Generation in recovering Heroin users: a comparative analysis of legal and illegal earning. J Offender Rehabil. 2015, 54:338-49. 10.1080\/10509674.2015.1043479","journal-title":"J Offender Rehabil"},{"key":"ref3","article-title":"Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Murray C","year":"2016","unstructured":"Murray C, Vos T, Lozano R, et al.. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2016, 380:2197-223. 1016\/S0140-6736(12)61689-4","journal-title":"Lancet"},{"key":"ref4","unstructured":"Opioid abuse and homelessness. (2016). Accessed. August 1, 2021: https:\/\/endhomelessness.org\/resource\/opioid-abuse-and-homelessness\/."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S242984","article-title":"Budget impact analysis of the introduction of injectable prolonged-release buprenorphine on opioid use disorder care resource requirements","volume":"12","author":"Phillips-Jackson H","year":"2020","unstructured":"Phillips-Jackson H, Hallam C, Cullen N, Pearson T, Gilman M, Li L, Musgrave P. Budget impact analysis of the introduction of injectable prolonged-release buprenorphine on opioid use disorder care resource requirements. Clinicoecon Outcomes Res. 2020, 12:233-40. 10.2147\/CEOR.S242984","journal-title":"Clinicoecon Outcomes Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2013.09.009","article-title":"The politics of providing opioid pharmacotherapy","volume":"24","author":"Radcliffe P","year":"2013","unstructured":"Radcliffe P, Parkes T. The politics of providing opioid pharmacotherapy. Int J Drug Policy. 2013, 24:e6-10. 10.1016\/j.drugpo.2013.09.009","journal-title":"Int J Drug Policy"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S180641","article-title":"Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine","volume":"12","author":"Gilman M","year":"2018","unstructured":"Gilman M, Li L, Hudson K, Lumley T, Myers G, Corte C, Littlewood R. Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine. Patient Prefer Adherence. 2018, 12:2123-9. 10.2147\/PPA.S180641","journal-title":"Patient Prefer Adherence"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1159\/000320576","article-title":"Barriers to opioid substitution treatment access, entry and retention: a survey of opioid users, patients in treatment, and treating and non-treating physicians","volume":"17","author":"St\u00f6ver H","year":"2011","unstructured":"St\u00f6ver H. Barriers to opioid substitution treatment access, entry and retention: a survey of opioid users, patients in treatment, and treating and non-treating physicians. Eur Addict Res. 2011, 17:44-54. 10.1159\/000320576","journal-title":"Eur Addict Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3109\/09687637.2014.945511","article-title":"Outcomes of opioid-dependence treatment across Europe: Identifying opportunities for improvement","volume":"14","author":"Fischer G","year":"2012","unstructured":"Fischer G, Nava F, St\u00f6ver H, et al.. Outcomes of opioid-dependence treatment across Europe: Identifying opportunities for improvement. Heroin Addict Relat Clin Probl. 2012, 14:39-50. 10.3109\/09687637.2014.945511","journal-title":"Heroin Addict Relat Clin Probl"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/add.14636","article-title":"Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder","volume":"114","author":"Frost M","year":"2019","unstructured":"Frost M, Bailey GL, Lintzeris N, et al.. Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder. Addiction. 2019, 114:1416-26. 10.1111\/add.14636","journal-title":"Addiction"},{"key":"ref11","unstructured":"Long-term safety, tolerability and effectiveness of CAM2038 weekly and monthly buprenorphine depots for treatment of opioid dependence. AUS, Australian and European Phase 3 Study. (2017). Accessed: October 4, 2021: https:\/\/www.addiction-ssa.org\/images\/uploads\/StrangJ_Long-term_Safety_Tolerability_And_Effectiveness_Poster_Nov_17.pdf."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder a randomized clinical trial","volume":"178","author":"Lofwall MR","year":"2018","unstructured":"Lofwall MR, Walsh SL, Nunes EV, et al.. Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder a randomized clinical trial. JAMA Intern Med. 2018, 178:764-73. 10.1001\/jamainternmed.2018.1052","journal-title":"JAMA Intern Med"},{"key":"ref13","unstructured":"Summary of product characteristics - Buvidal. (2019). Accessed. August 1, 2021: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/buvidal-epar-product-information_en.pdf."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1159\/000432395","article-title":"Opioid maintenance treatment--a call for a joint European quality care approach","volume":"22","author":"Brandt L","year":"2016","unstructured":"Brandt L, Unger A, Moser L, Fischer G, Jagsch R. Opioid maintenance treatment--a call for a joint European quality care approach. Eur Addict Res. 2016, 22:36-51. 10.1159\/000432395","journal-title":"Eur Addict Res"},{"key":"ref15","unstructured":"FDA approves first once-monthly buprenorphine injection, a medication-assisted treatment option for opioid use disorder. (2017). Accessed. August 1, 2021: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-once-monthly-buprenorphine-injection-medicatio...."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S72543","article-title":"Advances in the delivery of buprenorphine for opioid dependence","volume":"11","author":"Rosenthal RN","year":"2017","unstructured":"Rosenthal RN, Goradia VV. Advances in the delivery of buprenorphine for opioid dependence. Drug Des Devel Ther. 2017, 11:2493-505. 10.2147\/DDDT.S72543","journal-title":"Drug Des Devel Ther"},{"key":"ref17","unstructured":"FDA approves SUBLOCADE (Buprenorphine Extended-Release), the first and only once-monthly injectable buprenorphine formulation to treat moderate to severe opioid use disorder. (2017). Accessed. August 1, 2021: https:\/\/www.prnewswire.com\/news-releases\/fda-approves-sublocade-buprenorphine-extended-release-the-first-and-only-onc...."},{"key":"ref18","unstructured":"Camurus announces European Medicines Agency validation of CAM2038 Marketing Authorization application for treatment of opioid dependence. (2017). Accessed. August 1, 2021: https:\/\/www.newswire.ca\/news-releases\/camurus-announces-european-medicines-agency-validation-of-cam2038-marketing-aut...."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/add.15627","article-title":"Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings","author":"Dunlop AJ","year":"2021","unstructured":"Dunlop AJ, White B, Roberts J, et al.. Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings. Addiction. 2021, 10.1111\/add.15627","journal-title":"Addiction"},{"key":"ref20","unstructured":"Evidence review opioid dependence. buprenorphine prolonged- release injection (Buvidal). (2019). Accessed: August 1, 2021: https:\/\/www.nice.org.uk\/advice\/es19\/evidence\/evidence-review-pdf-6666819661."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S256714","article-title":"OUD care service improvement with prolonged-release buprenorphine in prisons: cost estimation analysis","volume":"12","author":"Wright N","year":"2020","unstructured":"Wright N, Hard J, Fearns C, et al.. OUD care service improvement with prolonged-release buprenorphine in prisons: cost estimation analysis. Clinicoecon Outcomes Res. 2020, 12:499-504. 10.2147\/CEOR.S256714","journal-title":"Clinicoecon Outcomes Res"},{"key":"ref22","article-title":"A technique for the measurement of attitudes","volume":"22","author":"Likert R","year":"1932","unstructured":"Likert R. A technique for the measurement of attitudes. Arch Psychol. 1932, 22:55.","journal-title":"Arch Psychol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/72443-prolonged-release-buprenorphine-therapy-in-opioid-use-disorder-can-address-stigma-and-improve-patient-quality-of-life","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:30:59Z","timestamp":1707507059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/72443-prolonged-release-buprenorphine-therapy-in-opioid-use-disorder-can-address-stigma-and-improve-patient-quality-of-life"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,5]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.18513","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10,5]]}}}